Clinical trials: Age
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity.
- Trial name
- MACURELI (NCT00549055)
- Testing
- Macugen
- Where
- 4 sites in Belgium
- Volunteers
- 38 people
- Sponsor
- Pfizer
Age-related Macular Degeneration
Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
To define what procedures were used for the diagnosis and monitoring of the treatment age-related macular degeneration (AMD). What is the effect of the Macugen, compliance with Macugen treatment, safety profile of Macugen, final…
- Trial name
- NCT00787319
- Testing
- no intervention
- Where
- 11 sites in Czechia
- Volunteers
- 108 people
- Sponsor
- Pfizer
Age-related Hearing Impairment 1, Personal Communication
The Baltimore HEARS Pilot Study
The primary purpose of the study is to develop and test the preliminary efficacy of a first-in-kind community-based intervention to provide affordable, accessible and effective hearing health care to low-income, minority older…
- Trial name
- HEARS (NCT02045511)
- Testing
- Baltimore HEARS
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Age-Related Hearing Loss
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss
This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.
- Trial name
- CLARITY-1 (NCT02345031)
- Testing
- AUT00063
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Autifony Therapeutics Limited
Exudative Age-related Macular Degeneration
ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
The purpose of this study is to test the hypothesis that proton beam irradiation combined with intravitreal anti-VEGF therapy is safe and potentially more effective than intravitreal anti-VEGF therapy alone in eyes with exudative…
- Trial name
- PBAMD2 (NCT01213082)
- Testing
- 24GyE proton and Anti-VEGF, 16GyE and anti-VEGF
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, Davis
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
Neovascular Age-Related Macular Degeneration
Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
The purpose of this study is to assess the systemic pharmacokinetics (PK) and safety of 2 different doses of brolucizumab (3 milligrams (mg)/50 microliters (μL) and 6 mg/50 μL) when administered at 4-week intervals for a total of…
- Trial name
- NCT02507388
- Testing
- Brolucizumab 3 mg/50 μL, Brolucizumab 6 mg/50 μL
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Age Related Macular Degeneration
A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
This is a single-masked study to compare intravitreally administered 0.5 mg ranibizumab to 2.0 mg ranibizumab in subjects who manifest persistent or recurrent macular fluid less than 30 days following treatment with intravitreal…
- Trial name
- LAST (NCT01115556)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Age-Related Macular Degeneration, Macular Degeneration
Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration
To evaluate the visual outcome and number of injections required during an optical coherence tomography (OCT)-guided treat and extend regimen with intravitreal aflibercept for treatment of subfoveal neovascular age-related…
- Trial name
- ATLAS (NCT01773954)
- Testing
- Intravitreal Aflibercept Injection
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MidAtlantic Retina
Exudative Age Related Macular Degeneration
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
To determine safety and efficacy of intravitreal injections of Sirolimus with adjunct EYLEA in subjects with exudative age related macular degeneration (AMD) with persistent intraretinal or subretinal edema due to neovascular AMD…
- Trial name
- NCT02732899
- Testing
- Sirolimus, EYLEA
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Study is Open to Seniors Age 50 or Older
Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center
The overall goals of this program are to measure the impact of a pharmacist pneumococcal vaccine education program (PPVP) using a senior center model of care and provide the pneumococcal vaccine to eligible participants.
- Trial name
- PPVP (NCT01944462)
- Testing
- Pharmacist Pneumococcal Vaccine Program (PPVP)
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Age - Related Macular Degeneration (AMD)
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to…
- Trial name
- RE-VIEW (NCT01722045)
- Testing
- Intravitreal Aflibercept Injection (IAI)
- Where
- 49 sites in United States
- Volunteers
- 154 people
- Sponsor
- Regeneron Pharmaceuticals
Age-related Macular Degeneration
Head to Head Study of Anti-VEGF Treatment.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular…
- Trial name
- RELIANCE (NCT02577107)
- Testing
- ranibizumab, Conbercept
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Small Gestational Age (SGA)
Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age
Multicentric, open-label, randomized, pilot comparative study in parallel groups comparing 1 group of subjects receiving 0.057 milligram/kilogram/day (mg/kg/day) or 0.40 mg/kg/week of Saizen® during 1 year to 1 group receiving…
- Trial name
- SGA OPTIMIS (NCT00249821)
- Testing
- Saizen®
- Volunteers
- 22 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Age Related Macular Degeneration
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable…
- Trial name
- NCT00593450
- Testing
- ranibizumab, bevacizumab
- Where
- 59 sites in United States
- Volunteers
- 1,208 people
- Sponsor
- University of Pennsylvania
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
This study will evaluate and compare two individualized ranibizumab treatment regimens in patients with neovascular (wet) AMD aiming to achieve and to maintain a maximum visual function benefit, while aiming to avoid unnecessary…
- Trial name
- OCTAVE (NCT01780935)
- Testing
- Ranibizumab
- Where
- 92 sites in Argentina, Austria and 22 more
- Volunteers
- 671 people
- Sponsor
- Novartis Pharmaceuticals
Foetal Growth Problem, Small for Gestational Age
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
This study is conducted in Japan. The aim of this trial is to assess the efficacy and safety of somatropin in children born small for gestational age (SGA) in Japan.
- Trial name
- NCT00184717
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 98 people
- Sponsor
- Novo Nordisk A/S
Age Related Macular Degeneration
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
The investigators hope to determine if "wet" AMD patients differ from patients with "dry" AMD or normal eyes in the production of anti-retinal pigment epithelium (anti-RPE) or anti-retinal antibody formation.
- Trial name
- Antibody (NCT00931489)
- Testing
- ranibizumab (Lucentis(R))
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Lawrence S. Morse, MD
Sleep Apnea, Age
Determinants of Age Related Breathing Instability During Non-Rapid-Eye-Movement (NREM) Sleep
The purpose for this research protocol was to examine the role of breathing control mechanisms that determine the development of sleep-disordered breathing in the elderly.
- Trial name
- NCT00732199
- Testing
- 1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development